Skip to main content
. 2007 Dec;1(4):377–392.

Table 9.

Proposed HDAC inhibitor combination strategies in CTCL

HDACi* + bexarotene: all stages
HDACi* + ECP + bexarotene: Sézary syndrome
HDACi* + methylation inhibitors
HDACi* + chemotherapy for induction and Tx of advanced disease
Topical HDACi* for early-stage disease
*

Vorinostat and/or depsipeptide.